Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573443 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
A Phase 3 study, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT00573443: Completed Phase 3 study, sponsored by Avanir Pharmaceuticals.
NCT00573443 is a Phase 3 study that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 326 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00573443, a Phase 3 study, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \[AVP-923-30\] or 20 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \[AVP-923-20\]) when compared to placebo, for the treatment of PBA in a population of patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS) over a 12-week period. An additional objective is to determine the pharmacokinetic parameters of the two different doses of AVP-923 in a subset of the study population. Pseudobulbar Affect (PBA) is a condition characterized by involuntary, sudden and frequent episodes of laughing and/or crying out of proportion or incongruous to the underlying emotion of happiness or sadness Other terms used to describe this condition include emotional lability, emotionalism, emotional incontinence, emotional discontrol, excessive emotionalism, and pathological laughing and crying. The outbursts can occur spontaneously or in response to provocative stimuli such as questions or events. A body of evidence suggests that PBA can be modulated through pharmacologic intervention. Dextromethorphan (DM) is a low-affinity uncompetitive antagonist of the N-Methyl-D-aspartate (NMDA) receptor, reducing the level of excitatory activity. DM also acts at the phencyclidine-binding site, which is part of the NMDA receptor complex. DM is a sigma receptor agonist, suppressing the release of excitatory neurotransmitters. Quinidine (Q) is a known potent inhibitor of cytochrome P450 2D6 (CYP2D6), that decreases the metabolism of dextromethorphan and helps to achieve sustained and therapeutic levels of this drug.
Primary Outcome
Episodes were counted each day and recorded in a daily diary. The outcome measure is the ratio of the episode rate over the 84-day treatment period to the rate during the baseline period, adjusted for study site, and underlying disease using longitudinal negative binomial regression.
Interventions
- DRUG Placebo
- DRUG dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
- DRUG dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
What the finished NCT00573443 record still lists
NCT00573443 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00573443 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00573443 about?
NCT00573443 is a clinical study titled "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS". Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \[AVP-923-30\] or 20 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \...
What is the current status of trial NCT00573443?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2007-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00573443?
The interventions under investigation include: Placebo (DRUG), dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg (DRUG), dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg (DRUG).
Who is sponsoring clinical trial NCT00573443?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00573443's enrollment target sits among peer trials
326 1075th of 2000 higher than 925 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT06586619 · 326 participants · NA
A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV
- NCT07040566 · 326 participants · Phase 2
A Trial of Varenicline for E-cigarette Cessation
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia